Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer

Aditya Bardia, Erin T. Arieas, Zhe Zhang, Andrew Defilippis, Karineh Tarpinian, Stacie Jeter, Anne Nguyen, N. Lynn Henry, David A. Flockhart, Daniel F. Hayes, Jill Hayden, Anna Maria Storniolo, Deborah K. Armstrong, Nancy E. Davidson, John Fetting, Pamela Ouyang, Antonio C. Wolff, Roger S. Blumenthal, M. Dominique Ashen, Vered Stearns

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The majority of breast cancers are diagnosed in postmenopausal women. Competing comorbidities, particularly cardiovascular disease (CVD), should be considered when individualizing adjuvant therapies for these women. We compared the 10-year predicted breast cancer recurrence risk with CVD risk among postmenopausal women with hormone receptor-positive (HR+), non-metastatic breast cancer. CVD risk factor data were prospectively collected from postmenopausal women with stage I-III, HR+ breast cancer initiating adjuvant aromatase inhibitor therapy. We compared predicted 10-year CVD risk, including the composite index heart age, computed from modified Framingham risk score, with predicted 10-year risk of breast cancer recurrence using Adjuvant! Online. We created multivariable logistic regression models to estimate the odds ratios (OR) and 95% confidence intervals (CI) for greater CVD risk than breast cancer recurrence risk. Among 415 women, mean age and heart age were 60 and 67 years, respectively. Overall, 43% of women had a predicted 10-year CVD risk equivalent to breast cancer recurrence risk and 37% had CVD risk higher than breast cancer recurrence risk. Predicted CVD risk was higher than breast cancer recurrence risk for stage I disease (OR: 6.1, 95% CI: 3.4-11.2) or heart age >65 (OR: 12.4, 95% CI: 7.0-22.6). The majority of postmenopausal women with HR+ early breast cancer had a predicted 10-year CVD risk that was equivalent to or higher than breast cancer recurrence risk. Physicians should weigh competing risks and offer early screening and cardiac prevention strategies for women at a greater risk for CVD.

Original languageEnglish
Pages (from-to)907-914
Number of pages8
JournalBreast Cancer Research and Treatment
Volume131
Issue number3
DOIs
StatePublished - Feb 2012

Fingerprint

Cardiovascular Diseases
Breast Neoplasms
Recurrence
Incidence
Odds Ratio
Confidence Intervals
Logistic Models
Aromatase Inhibitors
Comorbidity
Hormones

Keywords

  • Adjuvant! Online
  • Breast cancer risk
  • Cancer survivorship
  • Cardiovascular disease risk
  • Modified Framingham risk score

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. / Bardia, Aditya; Arieas, Erin T.; Zhang, Zhe; Defilippis, Andrew; Tarpinian, Karineh; Jeter, Stacie; Nguyen, Anne; Henry, N. Lynn; Flockhart, David A.; Hayes, Daniel F.; Hayden, Jill; Storniolo, Anna Maria; Armstrong, Deborah K.; Davidson, Nancy E.; Fetting, John; Ouyang, Pamela; Wolff, Antonio C.; Blumenthal, Roger S.; Ashen, M. Dominique; Stearns, Vered.

In: Breast Cancer Research and Treatment, Vol. 131, No. 3, 02.2012, p. 907-914.

Research output: Contribution to journalArticle

Bardia, A, Arieas, ET, Zhang, Z, Defilippis, A, Tarpinian, K, Jeter, S, Nguyen, A, Henry, NL, Flockhart, DA, Hayes, DF, Hayden, J, Storniolo, AM, Armstrong, DK, Davidson, NE, Fetting, J, Ouyang, P, Wolff, AC, Blumenthal, RS, Ashen, MD & Stearns, V 2012, 'Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer', Breast Cancer Research and Treatment, vol. 131, no. 3, pp. 907-914. https://doi.org/10.1007/s10549-011-1843-1
Bardia, Aditya ; Arieas, Erin T. ; Zhang, Zhe ; Defilippis, Andrew ; Tarpinian, Karineh ; Jeter, Stacie ; Nguyen, Anne ; Henry, N. Lynn ; Flockhart, David A. ; Hayes, Daniel F. ; Hayden, Jill ; Storniolo, Anna Maria ; Armstrong, Deborah K. ; Davidson, Nancy E. ; Fetting, John ; Ouyang, Pamela ; Wolff, Antonio C. ; Blumenthal, Roger S. ; Ashen, M. Dominique ; Stearns, Vered. / Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. In: Breast Cancer Research and Treatment. 2012 ; Vol. 131, No. 3. pp. 907-914.
@article{bc785662dd8e4f02be5bd55f2d1eeb16,
title = "Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer",
abstract = "The majority of breast cancers are diagnosed in postmenopausal women. Competing comorbidities, particularly cardiovascular disease (CVD), should be considered when individualizing adjuvant therapies for these women. We compared the 10-year predicted breast cancer recurrence risk with CVD risk among postmenopausal women with hormone receptor-positive (HR+), non-metastatic breast cancer. CVD risk factor data were prospectively collected from postmenopausal women with stage I-III, HR+ breast cancer initiating adjuvant aromatase inhibitor therapy. We compared predicted 10-year CVD risk, including the composite index heart age, computed from modified Framingham risk score, with predicted 10-year risk of breast cancer recurrence using Adjuvant! Online. We created multivariable logistic regression models to estimate the odds ratios (OR) and 95{\%} confidence intervals (CI) for greater CVD risk than breast cancer recurrence risk. Among 415 women, mean age and heart age were 60 and 67 years, respectively. Overall, 43{\%} of women had a predicted 10-year CVD risk equivalent to breast cancer recurrence risk and 37{\%} had CVD risk higher than breast cancer recurrence risk. Predicted CVD risk was higher than breast cancer recurrence risk for stage I disease (OR: 6.1, 95{\%} CI: 3.4-11.2) or heart age >65 (OR: 12.4, 95{\%} CI: 7.0-22.6). The majority of postmenopausal women with HR+ early breast cancer had a predicted 10-year CVD risk that was equivalent to or higher than breast cancer recurrence risk. Physicians should weigh competing risks and offer early screening and cardiac prevention strategies for women at a greater risk for CVD.",
keywords = "Adjuvant! Online, Breast cancer risk, Cancer survivorship, Cardiovascular disease risk, Modified Framingham risk score",
author = "Aditya Bardia and Arieas, {Erin T.} and Zhe Zhang and Andrew Defilippis and Karineh Tarpinian and Stacie Jeter and Anne Nguyen and Henry, {N. Lynn} and Flockhart, {David A.} and Hayes, {Daniel F.} and Jill Hayden and Storniolo, {Anna Maria} and Armstrong, {Deborah K.} and Davidson, {Nancy E.} and John Fetting and Pamela Ouyang and Wolff, {Antonio C.} and Blumenthal, {Roger S.} and Ashen, {M. Dominique} and Vered Stearns",
year = "2012",
month = "2",
doi = "10.1007/s10549-011-1843-1",
language = "English",
volume = "131",
pages = "907--914",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer

AU - Bardia, Aditya

AU - Arieas, Erin T.

AU - Zhang, Zhe

AU - Defilippis, Andrew

AU - Tarpinian, Karineh

AU - Jeter, Stacie

AU - Nguyen, Anne

AU - Henry, N. Lynn

AU - Flockhart, David A.

AU - Hayes, Daniel F.

AU - Hayden, Jill

AU - Storniolo, Anna Maria

AU - Armstrong, Deborah K.

AU - Davidson, Nancy E.

AU - Fetting, John

AU - Ouyang, Pamela

AU - Wolff, Antonio C.

AU - Blumenthal, Roger S.

AU - Ashen, M. Dominique

AU - Stearns, Vered

PY - 2012/2

Y1 - 2012/2

N2 - The majority of breast cancers are diagnosed in postmenopausal women. Competing comorbidities, particularly cardiovascular disease (CVD), should be considered when individualizing adjuvant therapies for these women. We compared the 10-year predicted breast cancer recurrence risk with CVD risk among postmenopausal women with hormone receptor-positive (HR+), non-metastatic breast cancer. CVD risk factor data were prospectively collected from postmenopausal women with stage I-III, HR+ breast cancer initiating adjuvant aromatase inhibitor therapy. We compared predicted 10-year CVD risk, including the composite index heart age, computed from modified Framingham risk score, with predicted 10-year risk of breast cancer recurrence using Adjuvant! Online. We created multivariable logistic regression models to estimate the odds ratios (OR) and 95% confidence intervals (CI) for greater CVD risk than breast cancer recurrence risk. Among 415 women, mean age and heart age were 60 and 67 years, respectively. Overall, 43% of women had a predicted 10-year CVD risk equivalent to breast cancer recurrence risk and 37% had CVD risk higher than breast cancer recurrence risk. Predicted CVD risk was higher than breast cancer recurrence risk for stage I disease (OR: 6.1, 95% CI: 3.4-11.2) or heart age >65 (OR: 12.4, 95% CI: 7.0-22.6). The majority of postmenopausal women with HR+ early breast cancer had a predicted 10-year CVD risk that was equivalent to or higher than breast cancer recurrence risk. Physicians should weigh competing risks and offer early screening and cardiac prevention strategies for women at a greater risk for CVD.

AB - The majority of breast cancers are diagnosed in postmenopausal women. Competing comorbidities, particularly cardiovascular disease (CVD), should be considered when individualizing adjuvant therapies for these women. We compared the 10-year predicted breast cancer recurrence risk with CVD risk among postmenopausal women with hormone receptor-positive (HR+), non-metastatic breast cancer. CVD risk factor data were prospectively collected from postmenopausal women with stage I-III, HR+ breast cancer initiating adjuvant aromatase inhibitor therapy. We compared predicted 10-year CVD risk, including the composite index heart age, computed from modified Framingham risk score, with predicted 10-year risk of breast cancer recurrence using Adjuvant! Online. We created multivariable logistic regression models to estimate the odds ratios (OR) and 95% confidence intervals (CI) for greater CVD risk than breast cancer recurrence risk. Among 415 women, mean age and heart age were 60 and 67 years, respectively. Overall, 43% of women had a predicted 10-year CVD risk equivalent to breast cancer recurrence risk and 37% had CVD risk higher than breast cancer recurrence risk. Predicted CVD risk was higher than breast cancer recurrence risk for stage I disease (OR: 6.1, 95% CI: 3.4-11.2) or heart age >65 (OR: 12.4, 95% CI: 7.0-22.6). The majority of postmenopausal women with HR+ early breast cancer had a predicted 10-year CVD risk that was equivalent to or higher than breast cancer recurrence risk. Physicians should weigh competing risks and offer early screening and cardiac prevention strategies for women at a greater risk for CVD.

KW - Adjuvant! Online

KW - Breast cancer risk

KW - Cancer survivorship

KW - Cardiovascular disease risk

KW - Modified Framingham risk score

UR - http://www.scopus.com/inward/record.url?scp=84856222995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856222995&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1843-1

DO - 10.1007/s10549-011-1843-1

M3 - Article

VL - 131

SP - 907

EP - 914

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -